DrugPatentWatch Database Preview
Provensis Company Profile
What is the competitive landscape for PROVENSIS, and when can generic versions of PROVENSIS drugs launch?
PROVENSIS has one approved drug.
There are fourteen US patents protecting PROVENSIS drugs.
There are one hundred and sixty-nine patent family members on PROVENSIS drugs in thirty-nine countries.
Summary for Provensis
| International Patents: | 169 |
| US Patents: | 14 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Provensis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 7,604,185 | Start Trial | Y | Y | Start Trial | ||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 7,814,943 | Start Trial | Y | Start Trial | |||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 7,842,282 | Start Trial | Start Trial | ||||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 7,842,283 | Start Trial | Y | Start Trial | |||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 7,025,290 | Start Trial | Y | Start Trial | |||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-002 | Dec 21, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 8,734,833 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Provensis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RE38919 | Start Trial |
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RE40640 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Provensis Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 1673293 | Start Trial |
| Spain | 2366399 | Start Trial |
| Portugal | 1694292 | Start Trial |
| Portugal | 1637127 | Start Trial |
| Russian Federation | 2261700 | Start Trial |
| Austria | 509863 | Start Trial |
| Portugal | 1673293 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
